Cited by

• Successful treatment of lipofibromatosis-like neural tumor of the lumbar spine with an NTRK-fusion inhibitor.

  Dupuis M, Shen Y, Curcio C, Meis JM, Wang WL, Amini B, Rhines L, Reuther J, Roy A, Fisher KE, Conley AP, Andrew Livingston J. Dupuis M, et al. Clin Sarcoma Res. 2020 Aug 6;10:14. doi: 10.1186/s13569-020-00136-6. eCollection 2020. Clin Sarcoma Res. 2020. PMID: 32782782 Free PMC article.
• Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101.

  Nagasubramanian R, Wei J, Gordon P, Rastatter JC, Cox MC, Pappo A. Nagasubramanian R, et al. Pediatr Blood Cancer. 2016 Aug;63(8):1468-70. doi: 10.1002/pbc.26026. Epub 2016 Apr 19. Pediatr Blood Cancer. 2016. PMID: 27093299 Free PMC article.
• A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report.

  Zhou N, Schäfer R, Li T, Fang M, Liu L. Zhou N, et al. BMC Cancer. 2018 Aug 22;18(1):842. doi: 10.1186/s12885-018-4749-z. BMC Cancer. 2018. PMID: 30134855 Free PMC article.
• Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.

  Hsiao SJ, Zehir A, Sireci AN, Aisner DL. Hsiao SJ, et al. J Mol Diagn. 2019 Jul;21(4):553-571. doi: 10.1016/j.jmoldx.2019.03.008. Epub 2019 May 7. J Mol Diagn. 2019. PMID: 31075511 Free PMC article. Review.
• Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.

  Vanden Borre P, Schrock AB, Anderson PM, Morris JC 3rd, Heilmann AM, Holmes O, Wang K, Johnson A, Waguespack SG, Ou SI, Khan S, Fung KM, Stephens PJ, Erlich RL, Miller VA, Ross JS, Ali SM. Vanden Borre P, et al. Oncologist. 2017 Mar;22(3):255-263. doi: 10.1634/theoncologist.2016-0279. Epub 2017 Feb 16. Oncologist. 2017. PMID: 28209747 Free PMC article.